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Abstract 
Background: Among people with chronic kidney disease (CKD) on dialysis, sub-optimal fluid management has been 
linked with hospitalisation, cardiovascular complications and death. This study assessed the cost-effectiveness using 
multiple-frequency bioimpedance guided fluid management versus standard fluid management based on clinical 
judgment.
Methods: A Markov model was developed to compare expected costs, outcomes and quality adjusted life years 
of the alternative management strategies. The relative effectiveness of the bioimpedance guided approach was 
informed by a systematic review of clinical trials, and focussed reviews were conducted to identify baseline event 
rates, costs and health state utility values for application in the model. The model was analysed probabilistically and a 
value of information (VOI) analysis was conducted to inform the value of conducting further research to reduce cur-
rent uncertainties in the evidence base.
Results: For the base-case analysis, the incremental cost-effectiveness ratio (ICER) for bioimpedance guided fluid 
management versus standard management was £16,536 per QALY gained. There was a 59% chance of the ICER being 
below £20,000 per QALY. Form the VOI analysis, the theoretical upper bound on the value of further research was £53 
million. The value of further research was highest for parameters relating to the relative effectiveness of bioimpedance 
guided management on final health outcomes.
Conclusions: Multiple frequency bioimpedance testing may offer a cost-effective approach to improve fluid man-
agement in patients with CKD on dialysis, but further research would be of value to reduce the current uncertainties.
Keywords: Multiple frequency bioimpedance devices, BCM—Body Composition Monitor, Cost-effectiveness, Value 
of information analysis
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco 
mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ 
zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
For people with chronic kidney disease (CKD) on dialy-
sis, assessing hydration status and the amount of fluid 
to remove during a dialysis session are important clini-
cal considerations. This has traditionally been a matter 
of clinical judgment, which can be unreliable leading 
to over or under-hydration and associated risks of 
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hospitalisation, cardiovascular (CV) complications and 
death [1–9]. These complications contribute substantially 
to the high economic burden that CKD places on health 
systems [10]. Thus, scope exists to improve health out-
comes and reduce costs to health services by improving 
fluid management decisions for dialysis patients.
In recent years, interest has grown in using multiple 
frequency bioimpedance devices to assess the hydration 
status of people on dialysis. These devices work by send-
ing painless electrical currents through the body via elec-
trodes, most commonly attached to the hand and foot 
[11]. Based on the impedance offered by different body 
tissues to different electrical frequencies, an algorithm is 
used to compute a person’s body composition (i.e. lean 
tissue, fat tissue, intracellular and extracellular water) 
[11–13]. In turn, this data can be used to estimate the 
amount of fluid that should be removed during dialysis in 
order to achieve normal levels of hydration.
In this study, we developed a health economic deci-
sion model to assess the cost-effectiveness of using a 
multiple frequency bioimpedance device to guide fluid 
management decisions in patients with CKD on dialysis, 
compared to the standard practice of relying on clinical 
judgment. The model was also used to identify gaps and 
sources of uncertainty in the existing evidence base, to 
help inform priorities for future research.
Methods
Model structure
A Markov model was developed in TreeAge Pro (TreeAge 
Software, Williamstown, MA, 2013). Full details of the 
model structure are published elsewhere [14].
Briefly, the model simulated the flow of a mixed dialysis 
cohort (mean age 66 years, 61% male, 87% on haemodi-
alysis (HD), 13% on peritoneal dialysis (PD)) through a 
set of discrete health states (Fig.  1). The distribution of 
the cohort across the model health states was updated 
on a fixed three-month cycle, based on a set of transi-
tion probabilities and clinical event rates derived from 
published literature. Costs and health state utility values 
were applied to the modelled health states and events, 
allowing cumulative costs and quality adjusted life years 
(QALYs) to be calculated for the alternative fluid man-
agement strategies over a 30-year time horizon.
Clinical parameters
Baseline event risks
The baseline risk of mortality in the dialysis popula-
tion was derived from the European Renal Association 
Fig. 1 State transition diagram showing the baseline model structure
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annual report [15]. A regression method was used to 
fit a Weibull function to the 5-year survival curve for 
a 60-year-old mixed dialysis cohort. The derived sur-
vival curve was adjusted to the starting age of the mod-
elled cohort (66 years) using a hazard ratio for mortality 
associated with increasing age in the renal replacement 
therapy (RRT) population [1]. To minimise uncertainty 
associated with the use of parametric curves to extrap-
olate long-term survival, age specific relative risks for 
mortality in the RRT population [1] were applied to UK 
general population age/sex specific mortality rates [16] 
beyond 10 years in the model.
To estimate transitions from dialysis to renal trans-
plant, we used the reported median time to transplant in 
the UK (1082 days) [17], applied to the proportion of the 
prevalent dialysis cohort waitlisted for transplant (13.5% 
for patients aged 65–75 years) [18]. No transplants were 
assumed to occur beyond the age of 75 in the model.
The ERA-EDTA Registry annual report [15] was used 
to inform post-transplant survival probabilities by type of 
donor (deceased/living) in the first year following trans-
plant. Beyond year one we utilised 10-year Kaplan Meier 
data from a UK population-based study of transplant 
recipients [19]. The method reported by Hoyle et al. [20] 
was used to reconstruct individual patient survival data 
for 2887 subjects aged 60–69  years, before fitting para-
metric survival curves using R statistical software [21]. A 
Weibull function was chosen for application in the model 
based on the Bayesian information criterion and was fur-
ther adjusted to the recipient’s age at time of transplant 
[19]. Beyond ten years, mortality in the post-transplant 
states was estimated by applying an adjusted relative 
risk [22] to age specific UK general population mortality 
rates.
Probabilities of unplanned hospitalisation were 
included in the model based on the first part of a pub-
lished two-part cost model [10] developed to predict 
annual inpatient hospitalisation costs in UK dialysis 
patients. This allowed for prediction of annual hospitali-
sation risk by age, dialysis modality, time on dialysis, and 
the presence of various comorbidities. These predicted 
probabilities were transformed into 3-monthly health 
state specific probabilities of hospitalisation for applica-
tion in the model. They were further disaggregated into 
CV (17.6%) and other causes (82.4%) using data reported 
by Rayner et  al. [23]. Incident CV hospitalisations were 
assumed to result in an increased comorbidity burden, 
increasing the probability of subsequent hospitalisations 
from the post-CV event health states.
Clinical effectiveness
A systematic review was conducted to inform the clinical 
effectiveness of multiple frequency bioimpedance guided 
fluid management versus standard fluid management for 
people with CKD on dialysis. The review, reported in 
detail elsewhere, [14] identified five relevant randomised 
controlled trials (RCTs) [24–29]. The length of follow-up 
ranged from 3 months to 2.5 years. The total number of 
randomised participants was 939.
The identified trials were powered primarily on sur-
rogate endpoints rather than final health outcomes. In 
a meta-analysis, both absolute overhydration and rela-
tive overhydration were found to be significantly lower 
in patients evaluated using BCM measurements to guide 
fluid management than for those evaluated using stand-
ard clinical methods [weighted mean difference − 0.44, 
95% confidence interval (CI) − 0.72 to − 0.15, p = 0.003, 
 I2 = 49%; and weighted mean difference − 1.84, 95% 
CI − 3.65 to − 0.03; p = 0.05,  I2 = 52%, respectively]. 
Pooled effects on systolic blood pressure (SBP) (mean 
difference − 2.46 mmHg, 95% CI − 5.07 to 0.15 mmHg; 
p = 0.06,  I2 = 0%), and arterial stiffness (mean difference 
− 1.18 m/s, 95% CI − 3.14 to 0.78 m/s; p = 0.24,  I2 = 92%), 
whilst not statistically significant, directionally favoured 
bioimpedance guided fluid management.
The mean reduction in arterial stiffness was consid-
ered the most robust predictor of plausible effects of bio-
impedance guided fluid management on non-fatal CV 
events and all-cause mortality in a dialysis population. 
Therefore, the mean reduction (measured as pulse wave 
velocity (PWV)) was combined with hazard ratios from 
a published observational study describing the relation-
ship between PWV and a composite outcome of all-cause 
mortality and non-fatal CV events [30]. Verbeke et  al. 
[30] showed that the relative effect per unit decrease in 
PWV in the dialysis population also decreased across ter-
tiles of aortic calcification. The weighted average of the 
reported hazard ratios (by aortic calcification tertiles) 
was therefore calculated (0.942, 95% CI 0.879–1.009) 
and then scaled in the model to the pooled mean reduc-
tion in PWV (− 1.18, 95% CI − 3.14 to 0.78) observed 
for bioimpedance spectroscopy versus standard clini-
cal assessment. The implementation of this approach 
used probabilistic sampling from distributions applied to 
both the pooled mean reduction in PWV, and the effect 
of a unit change in PWV. Therefore, the uncertainty sur-
rounding both these inputs was propagated through the 
model, with the estimated composite effect of bioimped-
ance guided fluid management on all-cause mortality 
and non-fatal CV hospitalisation being 0.932 (95% CI 
0.829–1.048).
Health state utility values
A focused search was conducted to identify health state 
utility values (HSUV) in people with ESRD. HSUVs 
reflect the desirability of different health states on scale 
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anchored by death (0) and full health (1), and can be 
combined with estimates of time (in years) spent in dif-
ferent health states to estimate QALYs.
Our search identified two previous systematic 
reviews which synthesised available HSUVs for modes 
of dialysis and transplant [31, 32]. The earlier meta-
analysis [31] was preferred since it was restricted to 
studies reporting HSUVs based on the EQ-5D instru-
ment. The reported pooled HSUVs were further 
adjusted relative to age related population norms in the 
model using a multiplicative approach [33]. In addi-
tion, published utility multipliers associated with CV 
events [33] were applied to patients experiencing inci-
dent CV events in the model. A utility decrement was 
also applied to hospitalisations for any other reasons, 
taken from an economic model developed to inform 
the National Institute for Health and Care Excellence 
(NICE) guideline on peritoneal dialysis [34]. Thus, the 
model was able to capture QALY gains associated with 
reductions in mortality, CV events and other cause 
hospitalisations.
Costs
Direct health service costs included in the model were 
those for dialysis [35], kidney transplantation [35], post-
transplant  follow-up and  immunosuppression [36–38], 
background medication (blood pressure medication [39, 
37] and erythropoietin stimulating agents [18, 37]), all 
cause inpatient hospitalisation [10], and outpatient costs 
[10]. An additional cost of quarterly bioimpedance moni-
toring was applied to those in the bioimpedance arm of 
the model. All costs were expressed in 2014/2015 pounds 
sterling. Modelled costs and QALYs were discounted at 
3.5%. Details on the applied costs are provided in Addi-
tional file 1.
The costs of all-cause inpatient hospitalisations were 
modelled based on age, type of dialysis, time on dialysis 
and comorbidity status using the cost model developed 
by Li et al. [10] The predicted hospitalisation costs were 
incorporated per inpatient admission and vary by health 
state and time varying characteristics of the modelled 
cohort. Annual outpatient costs for dialysis and trans-
plant patients were also taken from Li et al. [10] and were 
divided into quarterly costs for application in the model.
The additional cost per patient of bioimpedance test-
ing was calculated based on the device cost (BCM—
Body Composition Monitor), maintenance, consumables 
(electrodes and patient cards), and staff time. The total 
resources required for quarterly testing of patients 
was informed by a brief questionnaire sent to clinical 
experts based at six UK centres using multiple-frequency 
bioimpedance testing [14]. The average annual cost per 
patient year for quarterly testing came to £101.41.
Analysis
Whilst dialysis costs were included in the model, a deci-
sion was made to exclude them from the analysis since 
their inclusion would prohibit the ability of technologies 
that increase survival on dialysis to appear cost-effective 
at standard thresholds [40]. The model was analysed 
probabilistically using 1000 random draws from prob-
ability distributions assigned to each uncertain input 
parameter (Additional file 1). A cost-effectiveness scatter 
plot was used to present the uncertainty surrounding the 
modelled joint difference in costs and QALYs, and the net 
monetary benefit (NMB) framework was used to identify 
the proportion of model iterations favouring each strat-
egy at increasing cost-effectiveness thresholds (λ):
Further analysis was conducted to determine the 
expected value of perfect information (EVPI), and per-
fect parameter information (EVPPI) [41]. The EVPI and 
EVPPI calculations establish a theoretical upper bound 
on the value of further research to reduce current uncer-
tainties surrounding all the model input parameters and 
individual or specific groups of input parameters respec-
tively. The value of information analysis was conducted 
using the Sheffield Accelerated Value of Information 
(SAVI) tool [41].
EVPI calculations give an estimate of value of further 
research per individual patient. To scale these to the pop-
ulation level, information is required about the size of the 
population that stands to benefit over the expected lifes-
pan of the health technology in question. The population 
was set to the dialysis population in England and Wales 
in 2014 (27,804) [42, 43], and the useful lifespan of the 
bioimpedance technology was assumed to be 10 years.
Results
Cost effectiveness analysis (CEA)
The base case analysis showed that compared to clini-
cal judgment alone, multiple-frequency bioimpedance 
guided fluid management resulted in increased costs 
to the health service of £1896 per patient for an aver-
age QALY gain of 0.115 over the 30-year time horizon 
(Table  1). The corresponding incremental cost-effec-
tiveness ratio (ICER) was £16,536 per QALY gained. 
The probability of bioimpedance guided fluid manage-
ment being cost-effective was 59% at the cost-effective-
ness threshold of £20,000 per QALY gained. Figures  2 
and 3 further summarise the uncertainty surrounding 
the cost-effectiveness findings. As the cost-effectiveness 
threshold (per QALY gained) increases, the probability 
NMB =  ∗ Effect− Cost
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of cost-effectiveness asymptotes to ~ 83%, the simulated 
probability that bioimpedance guided management 
would generate health benefits compared to standard 
fluid management.  
Sensitivity analysis
Scenario analyses were conducted to explore the impact 
of uncertainty surrounding several key input parameters 
(Table 2). Under most of the scenarios tested, the point 
estimate of the ICER remained below £20,000 per QALY 
gained. However, when excluding the effect on mortality, 
the ICER increased to £40,282.
Value of information analysis
The EVPI for the decision between bioimpedance guided 
management and standard practice was £191 per patient 
and £53 million at the population level (Table  3). The 
EVPPI was highest (£187 per patient) for the parameter 
group determining the relative effect of bioimpedance 
guided fluid management on mortality and hospitalisa-
tion; i.e. the mean reduction in PWV and the hazard ratio 
per unit reduction in PWV. This suggests there would be 
value in conducting further trials powered to determine 
the clinical effectiveness of bioimpedance guided fluid 
management on these final health outcomes.
Discussion
Principal findings
This study found that compared to standard care, bioim-
pedance guided fluid management is expected to result 
in increased costs to the health service of £1,896 per 
patient, for an increase in QALYs of 0.115. The corre-
sponding incremental cost-effectiveness ratio is £16,536 
per QALY gained. However, substantial uncertainty sur-
rounds this point estimate, with there being a 41% chance 
that the ICER lies above the threshold of £20,000 per 
QALY.
Table 1 Base-case probabilistic cost-effectiveness scenario for bioimpedance guided fluid management versus standard practice 
(excluding dialysis costs)
Strategy Mean costs Incremental costs Mean QALYs Incremental QALYs ICER Probability cost-
effective at £20,000 
threshold
Clinical effectiveness: applying linked effects on mortality and non-fatal CV events through the pooled reduction in pulse wave velocity (HR = 0.9318 
on both CV events and mortality)
  Standard care £46,097 2.7031 0.407
  BCM £47,994 £1896 2.8177 0.1147 £16,536 0.593
Fig. 2 Incremental cost-effectiveness scatter plot: BCM—Body Composition Monitor versus standard care
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The value of information analysis indicates a high value 
in further research to reduce the current decision uncer-
tainty (EVPI = £53 million), with the highest value on 
parameters that drive the estimated effect of bioimped-
ance guided management on all-cause mortality and hos-
pital admissions.
Strengths and limitations
Key strengths of this study relate to the systematic 
approach used to develop and populate the economic 
model. The model structure itself was informed by a 
review of existing cost-effectiveness models in the area of 
CKD, and a systematic literature review of relevant RCTs 
was conducted to inform the clinical effectiveness inputs. 
Relevant registry data from the UK and Europe were 
also used to inform baseline mortality, all cause hospi-
talisation, and the probability of transplantation. This 
enhances the generalisability of the model findings to a 
prevalent, mixed dialysis population. In addition, a sur-
vey of clinical experts from centres experienced in using 
bioimpedance spectroscopy was undertaken to inform 
accurate costing of the testing pathway.
The key limitation relates to the availability of evi-
dence to inform the effect of bioimpedance guided fluid 
management on final health outcomes. Identified trials 
of clinical effectiveness focused primarily on surrogate 
markers such as hydration status (as measured by bioim-
pedance spectroscopy), SBP, left ventricular mass index 
(LVMI), and arterial stiffness (PWV).
We explored evidence for linking changes in hydration 
status to all-cause mortality and hospitalisation rates, but 
there is a lack of clear reference standard for hydration 
status and further uncertainty relating to the nature and 
shape of the relationship. Most of the bioimpedance trials 
have focused on overhydration as an outcome [25–29], 
but other studies point to the avoidance of underhydra-
tion as potentially being equally important for the avoid-
ance of vascular events [24, 44]. Furthermore, multiple 
fluid management parameters—including chronic vol-
ume expansion, ultrafiltration rate, and interdialytic 
weight gain—interact to affect CV morbidity and mor-
tality [44]. For example, whilst overhydration in people 
on dialysis is associated with mortality, so too is a high 
ultrafiltration rate. There is potentially a risk to patients 
if overhydration is managed by more rapid ultrafiltration. 
Therefore, we focussed on more distal markers of vascu-
lar pathology to inform the modelling.
A systematic review of LVMI as a treatment target in 
ESRD was conducted in 2014 and concluded that there 
was no clear and consistent association between inter-
vention-induced LVM change and all-cause or CV event-
related mortality [45]. Heerspink et al. [46]. conducted a 
meta-analysis of RCTs evaluating blood pressure lower-
ing medications in the dialysis population and estimated 
pooled relative risks of 0.71 (0.55 to 0.92) for CV events 
and 0.8 (0.66 to 0.96) for all-cause mortality, correspond-
ing to a mean reduction in SBP of 4.5 mmHg. However, it 
is uncertain if reductions in SBP induced by blood pres-
sure medication can be generalised to reductions in SBP 
induced by the management of fluid status. Therefore, a 
decision was made to model possible reductions in CV 
events and mortality through observed effects on arterial 
stiffness. Whilst there are limitations with this approach 
it serves to illustrate the potential for bioimpedance 
Fig. 3 Cost-effectiveness acceptability curves: BCM—Body Composition Monitor versus standard care
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testing to be cost-effective (with modest effects on CV 
events and mortality) whilst acknowledging the uncer-
tainty surrounding clinical effectiveness. Since all the 
clinical effectiveness evidence related to the BCM—Body 
Composition Monitor, generalisability of our findings 
to other multiple frequency bioimpedance devices is 
uncertain.
Table 2 Deterministic cost-effectiveness scenario analyses for bioimpedance guided fluid management versus standard practice 
(excluding dialysis costs)
Strategy Mean costs Incremental costs Mean QALYs Incremental QALYs ICER Net monetary 
benefit (£)
Base case: applying linked effects on mortality and non-fatal CV events, estimated through the pooled reduction in pulse wave velocity (HR of 0.9318 
applied to both all-cause mortality and CV hospitalisation)
  Standard care £46,234 2.7014 7793
  BCM £48,153 £1919 2.8170 0.1157 £16,587 8188
1. Alternative to base-case clinical effectiveness scenario: applying the point estimate for the pooled effect of BCM on non-fatal CV hospitalisation 
events only (through the pooled reduction in PWV (HR = 0.9318 on CV events only)
  Standard care £46,167 2.6976 7786
  BCM £46,391 £224 2.7032 0.0056 £40,282 7673
2. Alternative to base-case clinical effectiveness scenario: applying the point estimate for the pooled effect of BCM on mortality only (through the 
pooled reduction in PWV)
  Standard care £46,234 2.7014 7793
  BCM £55,579 £9345 3.2719 0.5706 £16,378 9859
3. Apply a 10% reduction in the use of blood pressure medications
  Standard care £46,234 2.7014 7793
  BCM £48,090 £1856 2.817 0.1157 £16,044 8250
4. Apply an increased cost of monitoring in adults by increasing the number of tests per patient to 12 annually (£229.65)
  Standard care £46,234 2.7014 7793
  BCM £48,774 £2540 2.817 0.1157 £21,953 7567
5. Assume bioimpedance guided management results in a 2% improvement in the health state utility over the lifetime of dialysis patients
  Standard care £46,234 2.7014 7793
  BCM £48,153 £1919 2.866 0.1646 £11,656 9166
6. Applying a smaller effect on mortality and non-fatal CV events (HR = 0.95 for both)
  Standard care £46,234 2.7014 7793
  BCM £47,757 £1523 2.7853 0.084 £18,135 7949
7. Applying a larger effect of bioimpedance monitoring on both CV events and mortality (0.844); consistent with the cross-sectional main effect of a 
unit change in PWV reported by Verbeke et al. [30]
  Standard care £46,234 2.7014 7793
  BCM £50,163 £3929 2.9791 0.2777 £14,145 9419
8. Excluding all non-CV event-related causes of hospitalisation from the analysis
  Standard care £32,111 2.711 22,109
  BCM £33,412 £1,301 2.826 0.115 £11,311 23,108
Table 3 Expected value of perfect information (EVPI) and perfect parameter information (EVPPI)
Parameter variables and groups Per Person EVPPI (£) Population 
EVPPI
Overall EVPI £191 £53,160,000
Group EVPPIs
Hazard ratio associated with a unit change in PWV £187 £52,086,005
Mean change in PWV (m/s)
Probability of graft failure with transplant from living donor £1.31 £364,500
Dose of ESA in HD patients £0.37 £104,000
Hazard ratio for mortality with transplant versus dialysis £0.30 £84,200
Costs 0 0
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Strengths and limitations with respect to other studies
To our knowledge, this is the first study to assess the 
cost-effectiveness of bioimpedance spectroscopy guided 
fluid management versus standard clinical management 
for the dialysis population. A review conducted by the 
Canadian Agency for Drugs and Technology in Health 
(~ CADTH) found insufficient evidence to support wide-
spread adoption of the technology, highlighting a lack of 
cost-effectiveness evidence as one of the gaps in the exist-
ing evidence base.
Meaning of the study
The model upon which the current analysis was based, 
was developed as part of Diagnostic Assessment Review 
commissioned by NICE in the UK [47]. Based on the 
assessment group report [48], the NICE appraisal com-
mittee concluded that there is currently not enough 
evidence (on final health outcomes) to recommend the 
routine adoption of multiple-frequency bioimpedance 
device monitoring to guide fluid management in people 
with CKD having dialysis in the NHS. Thus, instead the 
committee chose to support its use in research only, and 
encouraged centres already using the BCM—Body Com-
position Monitor to take part in further research and 
data collection. The results of our new value of informa-
tion analysis support this conclusion.
Recommendations for further research
Based on the value of information analysis reported here, 
it is clearly important that future research is designed to 
reduce the uncertainty surrounding longer-term effects 
on final health outcomes. Further research using multi-
ple frequency bioimpedance testing to assess fluid levels 
in dialysis patients is currently ongoing. The UK BISTRO 
(BioImpedance Spectroscopy To maintain Renal Out-
put Trial) trial [49] is evaluating the clinical and cost-
effectiveness of bioimpedance spectroscopy compared to 
standard clinical management of fluid levels in incident 
haemodialysis patients with some residual renal func-
tion. The primary outcome is time to anuria, but data on 
hospitalisation, critical events (including CV events and 
deaths), and patient reported outcomes are also being 
assessed as secondary endpoints. This data will help 
inform cost-effectiveness in the specific population, but 
further trials to inform the value of multiple-frequency 
bioimpedance monitoring more widely in the preva-
lent  dialysis population may also be warranted. Those 
centres that have already introduced routine multiple-
frequency bioimpedance device measurement for dialysis 
patients may also consider conducting adjusted retro-
spective analyses to estimate effects on clinically relevant 
and intermediate outcomes before and after introduction.
Strengthening of the evidence regarding the interrela-
tionships between fluid management parameters, more 
distal surrogate markers of vascular damage (e.g. fluid 
management-induced changes in blood pressure, arte-
rial stiffness), and consequent changes in mortality and 
hospitalisation events, would also be beneficial. Ideally, 
data from relevant randomised studies should be used 
to quantify relationships between intervention-induced 
changes in the surrogate end-points and longer-term 
changes in health outcomes.
Conclusion
In conclusion, the current evidence suggests that multi-
ple-frequency bioimpedance device measurement may 
be cost-effective way of improving fluid management 
in patients with CKD on dialysis. However, substantial 
uncertainties remain that would benefit from further 
research.
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